Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in MetastaticAdvanced Clear Cell Renal Cell Carcinoma
| ACET Stock | USD 0.96 0.04 4.35% |
Slightly above 55% of Adicet Bio's private investors are presently thinking to get in. The analysis of overall sentiment of trading Adicet Bio stock suggests that some investors are interested at this time. Adicet Bio's investing sentiment can be driven by a variety of factors including economic data, Adicet Bio's earnings reports, geopolitical events, and overall market trends.
Adicet |
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimm
Read at businesswire.com
 |
Adicet Bio Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Adicet Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Adicet Bio Fundamental Analysis
We analyze Adicet Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adicet Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adicet Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Adicet Bio is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Adicet Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adicet Bio stock to make a market-neutral strategy. Peer analysis of Adicet Bio could also be used in its relative valuation, which is a method of valuing Adicet Bio by comparing valuation metrics with similar companies.
Peers
Adicet Bio Related Equities
| ANEB | Anebulo Pharmaceuticals | 29.60 | ||||
| CGEM | Cullinan Oncology | 5.13 | ||||
| PLRX | Pliant Therapeutics | 4.00 | ||||
| IGMS | IGM Biosciences | 3.91 | ||||
| AADI | Aadi Bioscience | 3.33 | ||||
| NKTX | Nkarta | 2.98 | ||||
| GLUE | Monte Rosa | 2.41 | ||||
| AVTE | Aerovate Therapeutics | 1.15 | ||||
| KROS | Keros Therapeutics | 0.60 | ||||
| AGIO | Agios Pharm | 0.53 | ||||
| EWTX | Edgewise Therapeutics | 0.10 | ||||
| BCYC | Bicycle Therapeutics | 0.00 | ||||
| ACRV | Acrivon Therapeutics, | 0.64 | ||||
| STOK | Stoke Therapeutics | 0.71 | ||||
| ALEC | Alector | 1.62 | ||||
| TNYA | Tenaya Therapeutics | 3.01 | ||||
| VOR | Vor Biopharma | 4.77 |
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.